Advanced Urology Associates First in Will County to Offer New Enlarged Prostate Treatment
A new minimally invasive treatment for an enlarged prostate is an alternative to surgery, drugs and permanent implants.
Dr. Gregory Andros is the first in the Will County area to perform the iTind™ procedure for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.
“I am excited to be able to offer a new innovated minimally invasive office based BPH procedure. The iTIND technology now enables urologist to treat BPH while addressing a bladder neck obstruction without causing sexual side effects. This is the first technology that allows for treating BPH without long term medications, puncturing or removing prostate tissue.” said Dr. Greg Andros.
BPH is a noncancerous enlargement of the prostate and one of the most common diseases in aging men. BPH affects approximately 50% of men between the ages of 51 and 60 and up to 90% of men over the age of 80. BPH symptoms include frequent urination with a sense of urgency and a weak urinary stream, which can include excessive urination at night. Suffered over time, these symptoms can have a negative impact on overall quality of life. With most men facing BPH in their lifetimes, there is a need for more minimally invasive treatment options beyond drugs and surgery.
The iTind procedure involves the temporary placement of a nitinol device that reshapes the prostatic urethra without burning or cutting out tissue, and without leaving behind a permanent implant. The device remains in place for five to seven days while the patient is at home, and clinical trials have proven that, upon removal, patients experience immediate relief of their symptoms without any effect on their sexual function.
The iTind device is indicated for men aged 50 and above. As with any medical procedure, implantation of the iTind device comes with the possibility of side effects, including pelvic discomfort, blood in urine, painful or urgent urination. In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate.
1. What is Benign Prostatic Hyperplasia (BPH)? UrologyHealth.org. https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph). Updated September 2021. Accessed March 8, 2022.
2. Benign prostatic hyperplasia (BPH). Urology Care Foundation. Accessed November 12, 2021. https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph)
3. Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment–the QUALIPROST study. Int Urol Nephrol. 2016;48(5):645-656. doi:10.1007/s11255-015-1206-7
4. Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial [published online ahead of print, 2020 Dec 26]. Urology. 2020;S0090-4295(20)31520-X. DOI: 10.1016/j.urology.2020.12.022
Gregory J. Andros, M.D.
Dr. Andros has been a leading urologist in advanced urology care and treatment since 1998. Dr. Andros’ expertise and focus is on the latest technological advancements for minimally invasive surgeries and treatments for urological conditions including BPH, prostate cancer, overactive bladder (OAB) and vasectomy procedures.